Parameters of Blood Count and Tumor Markers in Patients with Borderline Ovarian Tumors: A Retrospective Analysis and Relation to Staging by Nomelini, Rosekeila Simões et al.
International Scholarly Research Network
ISRN Oncology
Volume 2012, Article ID 947831, 5 pages
doi:10.5402/2012/947831
Clinical Study
Parameters of BloodCount and TumorMarkers inPatients
withBorderlineOvarianTumors:A Retrospective Analysis
andRelation to Staging
Rosekeila Sim˜ oes Nomelini,1 Ta´ ısaMorete daSilva,1
Beatriz MartinsTavaresMurta,2 andEddieFernando CandidoMurta1
1Discipline of Gynecology and Obstetrics, Oncological Research Institute (IPON), Federal University of Triˆ angulo Mineiro, 38025-440
Uberaba, MG, Brazil
2Discipline of Pharmacology, Federal University of Triˆ angulo Mineiro, 38025-440 Uberaba, MG, Brazil
Correspondence should be addressed to Rosekeila Sim˜ oes Nomelini, rosekeila@terra.com.br
Received 16 January 2012; Accepted 20 February 2012
Academic Editor: A. E. Bilsland
Copyright © 2012 Rosekeila Sim˜ oes Nomelini et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
The aim of this paper was to evaluate the parameters of blood count and tumor markers in borderline ovarian tumors. We
evaluated 21 patients who had conﬁrmed histopathologic diagnosis of borderline ovarian tumor. We recorded age, parity, tumor
type, stage of cancer, serum levels of tumor markers (CA-125, CA-15.3, CA-19.9, CEA, AFP), and the parameters of blood count,
fasting glucose, disease-free survival and overall. The patients were divided into two groups, stage IA (n = 13) and stage IB-IIIC
(n = 8). The unpaired t-test and Fisher’s exact test were used, with P values of less than 0.05 being considered to indicate statistical
signiﬁcance. Levels of red blood cells, hematocrit, and hemoglobin were signiﬁcantly higher in stage IA when compared with stage
IB-IIIC (P<0.05). The levels of tumor marker CEA had a tendency to be higher in the group stage IB-IIIC (0.08). Abnormal
levels of CEA and CA-19.9 were found more frequently in stages IB-IIIC. Therefore, parameters of blood count, CEA, and CA-19.9
should be targeted for further research in identifying prognostic factors in borderline tumors.
1.Introduction
Borderline ovarian tumors were recognized as clinical and
pathological entity by the International Federation of Gyne-
cologyandObstetrics(FIGO)in1972andcompriseabout15
to 20% of all malignant ovarian tumors [1, 2]. Histologically,
the borderline tumors are deﬁned by the presence of nuclear
atypia, epithelial stratiﬁcation, mitotic activity, and absence
of stromal invasion [3, 4].
T h em o s tc o m m o nh i s t o l o g i ct yp e sa r es e r o u sa n dm u c i -
nous tumors. They are usually staged according to FIGO
but have a much better prognosis than invasive carcinomas
[5]. Borderline ovarian tumors are also described as tumors
with low malignant potential [6]. However, a subset of these
tumors may progress and be lethal [7], making the diagnosis
and treatment in cases of borderline tumors be still a
challenge.
Borderline ovarian tumors are diagnosed primarily in
young women who want to preserve their reproductive life
and,therefore,itisimportanttodeﬁneclinicalandhistologi-
calcriteriaforpatientsathighriskofobscuringtheprognosis
[8].
Studies of other molecular markers were not yet as reli-
able predictors of biological behavior; however, there is hope
that future studies of genetics and molecular biology of tu-
mors will provide the insertion of useful laboratory tests.
Other prognosis factors were DNA-ploidy, histologic type,
and age of patients [9].
Although patients have an excellent prognosis, recur-
rence risk remains in some cases. It was shown that the sur-
gical procedure, the rupture of the cyst, the staging, the pres-
ence of microinvasion, and peritoneal implants were the ﬁve
independent prognostic factors aﬀecting the recurrence of
these neoplasms [6, 7, 9, 10]. Emphasis should be provided2 ISRN Oncology
Table 1: Laboratory parameters (mean±standard deviation) in stage IA (n = 13) and IB-IIIC (n = 8) borderline ovarian tumors.
Stage IA Stages IB-IIIC
Red blood cells (×106/mm3)4 .78 ±0.47∗ 4.25 ±0.5
Hematocrit (%) 41.9 ±3.6∗∗ 36.91 ±5.13
Haemoglobin (g/100mL) 14.08 ±1.3∗∗∗ 12.37 ±1.9
Leucocytes (/mm3) 7,740 ±2,607.1 8,162.5 ±5,246.5
Platelets (/mm3) 259,076.92 ±58,150 310,857.14 ±88,494
Fasting glucose (mg/dL) 100.2 ±25.93 104.5 ± 28.05
CA-125 (U/mL) 60.47 ±132.86 4 .34 ± 59.43
CA-15.3 (U/mL) 41.12 ±53.55 28.85 ± 17.84
CA-19.9 (U/mL) 12.95 ±13.82 3 .84 ± 36.35
CEA (U/mL) 2.43 ±3.79 .86 ±12.48
AFP (U/mL) 1.43 ±0.65 1.42 ± 0.56
Unpaired t-test. ∗,∗∗,∗∗∗respectively, P<0.03, 0.01, 0.02, compared to stages IB-IIIC.
in those patients with high-risk factors and prevention strat-
egies should be taken to prevent its progression.
The aim of this study was to evaluate the parameters of
blood count and tumor markers in preoperative staging of
borderline ovarian tumors.
2.MaterialsandMethods
A retrospective study was conducted in the Departments of
Special Pathology and Discipline of Obstetrics and Gyne-
cology of UFTM. We evaluated 21 patients in the Pelvic
Mass Clinic in the Discipline of Obstetrics and Gynecology/
Oncology Research Institute (IPON) who were underwent
surgical treatment according to predetermined criteria [11,
12] and had conﬁrmed histopathologic diagnosis of border-
line ovarian tumor.
We recorded age, parity, tumor type, stage of cancer, type
of surgery, rupture of the cyst, chemotherapy, serum levels
of tumor markers (CA-125, CA-15.3, CA-19.9, CEA, AFP),
and the parameters of blood count (hemoglobin, WBC,
platelets), fasting glucose, disease-free survival, and overall.
The patients were divided into two groups, stage IA (n =
13) and stage IB-IIIC (n = 8). Regarding the histologic
type, tumors were divided into two groups, serous and
nonserous. The normal values for tumor markers were AFP
≤ 12.1ng/mL, CA 125 < 35U/mL, CA15.3 < 25U/mL, CA
19.9 < 39U/mL, and CEA ≤ 5.5ng/mL.
2.1. Statistical Analysis. Data were analyzed using GraphPad
Instat software. Values were expressed as means ± standard
deviations (SDs). Unpaired t-test was used to compare mean
values of laboratory parameters between stages I and IB-IIIC
and the mean values of laboratory parameters between the
nonserous and serous group. Fisher’s exact test was used to
evaluate normal and abnormal levels of tumor markers in
relation to groups of stages and histological type. The sig-
niﬁcance level was less than 0.05.
This research was approved by the Research Ethics Com-
mittee of Federal University of Triˆ angulo Mineiro.
3. Results
We evaluated 21 patients with borderline ovarian tumor.
The average age of patients was 50.05 ± 17.61 years. The
average parity was 2.4 ± 2.04 children. Thirteen patients
(61.9%)underwentbilateralsalpingoophorectomy,hysterec-
tomy, omentectomy, peritoneal washing, and multiple biop-
sies,andeight(38.1%)underwentunilateralorbilateralsalp-
ingoophorectomy. Thirteen patients (61.9%) were in stage
IA, 2 (9.52%) in stage IB, 3 (14.3%) in stage IC, 2 (9.52%)
in stage IIIA, and one (4.76%) in stage IIIC. Ten tumors
(47.6%) were mucinous, eight (38.1%) were serous, one
(4.75%) was endometrioid, one (4.75%) was a Brenner
tumor, and one (4.75%) was mucinous with benign Brenner.
Fifteen(71.4%)didnotreceivechemotherapy,and6(28.6%)
did. One (4.76%) patient died and 7 (33.33%) were lost to
follow up. In 17 (81%) patients there was no rupture of the
c y s ta n dr u p t u r e db y1 9 % .
In Table 1, patients were divided into two groups, one
with stage IA (n = 13) and the other with stage IB-IIIC
(n = 8), and the laboratory parameters were compared.
Levels of red blood cells, hematocrit, and hemoglobin were
signiﬁcantly higher in stage IA when compared with the
group stage IB-IIIC (P<0.03, P<0.01, and P<0.02,
resp.). The levels of tumor marker CEA had a tendency to
be higher in the group stage IB-IIIC, when compared to the
group stage IA (0.08). Table 2 compares the levels of tumor
markers among nonserous and serous subtypes, no statisti-
cally signiﬁcant diﬀerence being demonstrated.
Comparing the normal and abnormal values of tumor
markers in relation to the stages (Table 3), abnormal values
ofCA19.9andCEAwerefoundmorefrequentlyinthegroup
stages IB-IIIC (P = 0.0357 and P = 0.0006, resp.). Com-
paring the normal and abnormal values of tumor markers in
relation to the histological types (serous or nonserous), no
statistically signiﬁcant diﬀerence was demonstrated.
4. Discussion
The treatment of borderline ovarian tumors was similar to
their invasive counterparts for a long time. However, in view
of the good prognosis, its occurrence in a younger age group,ISRN Oncology 3
Table 2: Tumor markers (mean±standard deviation) in serous histological subtypes (n = 8) and nonserous (n = 13) borderline ovarian
tumors.
Serous Mean ± standard deviation Nonserous Mean ± standard deviation
CA-125 (U/mL) 44.87 ±59.99 75.19 ± 136.71
CA-15.3 (U/mL) 53.66 ±62.32 3 .19 ±11.31
CA-19.9 (U/mL) 7.01 ±5.01 24.95 ±29.38
CEA (U/mL) 1.31 ±1.22 7.67 ± 10.31
AFP (U/mL) 1.74 ±0.62 1.24 ±0.54
Unpaired t-test; P : not signiﬁcant.
Table 3: Increased tumour markers (n/total of cases) in relation to
groups of stages.
Stage IA % Stages IB-IIIC %
CA-125 (≥35U/mL) 2/10 20 4/6 66.7
CA-15.3 (≥25U/mL) 4/10 40 2/6 33.3
CA-19.9 (≥39U/mL) 1/10 10 4/6∗ 66.7
CEA (≥5.5ng/mL) 1/11 9.1 6/6∗∗ 100
AFP (≥12.1ng/mL) 0/11 0 0/5 0
Fisher’s exact test. ∗, ∗∗,r e s p e c t i v e l y ,P<0.0357 and 0.0006, compared to
stage I.
andthedevelopmentoflessinvasivetechniques,thequestion
that can be asked is whether a conservative treatment is
justiﬁed in these cases. The goal in treating cases of
borderline ovarian tumor is the deﬁnition of patients with
poor prognosis and risk factors for recurrence and therefore
requires more aggressive therapy. Research could help iden-
tify borderline tumors with poor prognosis [13].
Although borderline ovarian tumors have an excellent
prognosis, they are not free of risk of recurrence. Kokawa
et al. (2009) showed that less advanced staging which is the
absence of residual tumor, peritoneal implants and ovarian
stromal involvement, and negative peritoneal cytology were
signiﬁcantlyassociatedwithimprovedoverallsurvival.There
are insuﬃcient data to support a role for aggressive surgery
and adjuvant chemotherapy-prolonged survival [14]. Chang
et al. (2008) showed that the presence of invasive implants
and micropapillary pattern were important prognostic fac-
tors in patients with serous borderline ovarian tumors [15].
Genetic abnormalities may better delineate the relationship
between borderline tumors and carcinomas and lead to a
unifying hypothesis as to the origin of these important
ovarian lesions [7].
Some studies have shown changes in laboratory param-
eters of blood count and glucose related to the prognosis
of malignant neoplasms. A higher frequency of changes in
leukocytes in peripheral blood was found in patients with
advanced cancer of the cervix, and neutrophilia could be
an indicator of tumor invasiveness [16]. Another study
showed that patients with cervical neoplasias with poor
prognosis had higher plasma glucose levels than those
with less aggressive lesions [17]. In ovarian malignancies,
hemoglobin levels before and during chemotherapy may be
important prognostic factors [18–20], and the hemoglobin
concentration had a prognostic factor in oral squamous
carcinoma [21].
However most studies relating to blood count and prog-
nosis of cancer were performed in malignancies, and no sim-
ilar studies were performed in borderline ovarian tumors.
In our study, levels of red blood cells, hematocrit, and he-
moglobin were signiﬁcantly higher in stage IA when com-
pared with the group stage IB-IIIC.
Ovarian cancer patients had haematological anomalies
(haemoglobin and haematocrit levels were signiﬁcantly low-
er and the platelet count was higher, and lower values for
lymphocytes) compared to patients with benign ovarian
tumours [22]. Some studies have shown a possible relation-
ship with IL-6 levels of hemoglobin and platelets in malig-
nant disease. High pretreatment platelet counts and low
pretreatment hemoglobin levels can be negative prognostic
factors in patients with ovarian cancer; there was observed
the relationship of cystic ﬂuid IL-6 levels with platelet counts
and hemoglobin levels [23]. Another study demonstrated
that anaemia in advanced stages of ovarian cancer may be
related to the levels of IL-6 [24]. Therefore there can be a
possible causative role of tumor-derived IL-6 and abnormal
values in hemoglobin and platelet levels, which have been
recognized as prognostic factors. In our study, there were
no signiﬁcant changes in glucose levels, leukocytes, and
platelets.Thesmallamountofpatientsstudiedbecauseofthe
low frequency of borderline tumors may be a limiting factor.
In patients with borderline ovarian tumors, histological
type mucinous, preoperative CA 19.9 was more frequently
elevated than CA 125 or CEA, and abnormal levels of tumor
markers predicted recurrence in follow-up [25]. Our data
showed no signiﬁcant diﬀerence in tumor markers between
nonserous or serous group, perhaps by the small number of
patients when groups are stratiﬁed.
Studies with a larger number of patients who underwent
surgery for borderline ovarian tumors are needed to assess
its importance as a prognostic factor. The CA-125 levels
are may be higher in patients with borderline tumors
in more advanced stages. Kolwijck et al. demonstrated
preoperative serum CA-125 levels signiﬁcantly higher for
patients with advanced stage compared with patients with
stage I in borderline ovarian tumors [26]. Wu et al. showed
that stages II and III, only excision of the cyst (con-
serving ovarian tissue) and higher preoperative serum CA-
125 were independent variables predictive of recurrence in
these tumors [27]. Høgdall et al. showed that a shorter dis-
ease-speciﬁc survival for patients with 30% or higher CEA4 ISRN Oncology
expression in the tumour tissue and the highest CEA expres-
sion compared with no expression was found to be an inde-
pendent prognostic factor for mucinous ovarian cancer in
Danish patients [28]. In a preoperative comparison of serum
tumor markers, CA 125 and CA 19.9 levels were signiﬁcantly
higher in IC stages than those in IA stages [29]. CA 125
levels in our study were higher in stage IB-IIIC, but there was
nostatisticalsigniﬁcance.TheCEAlevelstendedtobehigher
also in these stagings. On the other hand, we found two
abnormal tumor markers (CA 19.9 and CEA) more fre-
quently in stages IB-IIIC compared with stage IA.
Some questions are still challenging. What are the high-
risk patients? In patients who received adjuvant chemother-
apy, would that provide beneﬁts? When surgery could be
performed preserving fertility in patients taking low risk of
relapse? To our knowledge, this is the ﬁrst study of literature
that relates blood count and staging of borderline ovarian
tumors.
5. Conclusions
Red blood cell count, hemoglobin, and hematocrit were
signiﬁcantly higher in borderline ovarian tumors on initial
staging (IA), and CEA levels tended to be higher in stage IB-
IIIC. Abnormal values of CA 19.9 and CEA were found more
frequently in the stages IB-IIIC. These laboratory parameters
should be targeted for further research in identifying prog-
nosticfactorsinborderlinetumors,guidingthemanagement
of these cases and indicating for each patient the right treat-
ment, so that it is less aggressive and may preserve fertility in
women over young, but do not leave these patients at risk
of an unfavorable evolution. Further studies with larger
numbers of patients are needed to elucidate the role of
laboratory parameters in the prognosis of borderline ovarian
tumor.
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